Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus for treatment-resistant pruritus in dialysis patients
IRCT20211222053485N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Jul 2025
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of tacrolimus in chronic kidney disease-associated pruritus (CKD-aP) and end-stage kidney disease (ESKD), sponsored by Shiraz University of Medical Sciences. Started Jul 2025; status: completed.
02
Drugs
tacrolimus
03
Conditions
chronic kidney disease-associated pruritus (CKD-aP)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on IRCT20211222053485N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211222053485N1.